CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
加利福尼亞州南舊金山，2024年11月27日（環球新聞通訊）-- CytomX Therapeutics, Inc.（納斯達克：CTMX），在被掩蔽的、條件激活的生物製品領域的領先者，今天宣佈首席執行官兼董事長Sean McCarthy博士將參加2024年第36屆派傑投資醫療會議的爐邊聊天，時間爲2024年12月4日，上午8:00（東部時間）。
A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
本次演講的直播網絡廣播將在CytomX網站的活動和演講頁面上提供。此外，管理層將與註冊參加會議的投資者進行一對一會議。
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and X (formerly Twitter).
關於cytomx生物製品公司
CytomX是一家臨床階段的以腫瘤爲重點的生物製藥公司，專注於開發新型條件激活的掩蔽型生物製品，以在腫瘤微環境中局部發揮作用。通過引領以其PROBODY治療平台爲動力的局部生物製品的新型產品線，CytomX的願景是爲癌症治療創造更安全、更有效的療法。CytomX的強大而獨特的產品線包括抗體-藥物結合物（ADCs）.電芯連接劑和細胞因子等免疫調節劑。CytomX的臨床階段產品線包括CX-904，CX-2051和CX-801。CX-904是一個掩蔽的，條件激活的t細胞連接劑，靶向腫瘤細胞上的表皮生長因子受體（EGFR）和t細胞上的CD3受體。CX-904與安進（Amgen）在全球共同開發聯盟中合作。CX-2051是一個掩蔽的，條件激活的ADC，定向靶向上皮細胞粘附分子（EpCAM），並攜帶頂體蛋白酶抑制劑藥效成分。CX-2051在多個表達EpCAM的上皮癌症中具有潛在適用性，並與AbbVie旗下的Immunogen合作發現。CX-801是一個掩蔽的干擾素α-20億次PROBODY細胞因子，對傳統的免疫治療敏感腫瘤以及不敏感（冷）腫瘤具有廣泛潛力適用性。CytomX已與腫瘤領域的多個領軍企業建立了戰略合作關係，包括安進（Amgen），阿斯利康（Astellas），百時美施貴寶（Bristol Myers Squibb），再生元（Regeneron）和Moderna。有關CytomX以及它如何努力將條件激活治療作爲針對癌症的新標準，更多信息請訪問該網站，並關注我們的LinkedIn和X（前身爲Twitter）頁面。
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
公司聯繫人：
克里斯•奧格登
高級副總裁，首席財務官
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
投資者聯繫人：
Precision AQ（前斯特恩投資者關係）
斯蒂芬妮•阿舍
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
媒體聯繫：
Redhouse Communications
特里•達爾曼
teri@redhousecomms.com
譯文內容由第三人軟體翻譯。
